Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
September 07, 2017 16:01 ET
|
Bellerophon Therapeutics Inc.
WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief...
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
September 05, 2017 08:30 ET
|
Bellerophon Therapeutics Inc.
WARREN, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive top line data from a Phase 2...
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
August 07, 2017 08:00 ET
|
Bellerophon Therapeutics Inc.
WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial...
Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
August 03, 2017 08:30 ET
|
Bellerophon Therapeutics Inc.
WARREN, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced agreement with the U.S. Food and Drug...
Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
May 22, 2017 16:01 ET
|
Bellerophon Therapeutics Inc.
Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in...
Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update
May 15, 2017 08:00 ET
|
Bellerophon Therapeutics Inc.
WARREN, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial...
Bellerophon Announces $3.0 Million Registered Direct Offering
May 10, 2017 08:00 ET
|
Bellerophon Therapeutics Inc.
WARREN, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive...
Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference
May 01, 2017 08:01 ET
|
Bellerophon Therapeutics Inc.
Data Show that INOpulse was Associated with Clinically Meaningful Improvements in Hemodynamics and Exercise Capacity in Difficult-to-Treat PH-IPF Patients Phase 2b Study in PH-IPF Population Planned ...
Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT)
April 07, 2017 07:00 ET
|
Bellerophon Therapeutics Inc.
Clinical Data Presented From an Investigator Led Study of INOpulse in PAH Patients at Western University, London, Ontario and Allegheny General Hospital, Pittsburgh, PA Study Reinforces Hemodynamic...